Copyright
©The Author(s) 2017.
World J Hepatol. Mar 28, 2017; 9(9): 469-476
Published online Mar 28, 2017. doi: 10.4254/wjh.v9.i9.469
Published online Mar 28, 2017. doi: 10.4254/wjh.v9.i9.469
Table 3 Diagnostic performance of serum alpha-fetoprotein and annexin A2 in the discrimination of patients with hepatocellular carcinoma from those with chronic liver disease
| Variable | Cut-off | Sn (%) | Sp (%) | NPV (%) | PPV (%) | Efficacy |
| AFP (ng/mL) | 19.8 | 70 | 96 | 61.5 | 97.2 | 78.7 |
| ANXA2 (ng/mL) | 18 | 74 | 88 | 62.9 | 92.5 | 78.7 |
- Citation: Shaker MK, Abdel Fattah HI, Sabbour GS, Montasser IF, Abdelhakam SM, El Hadidy E, Yousry R, El Dorry AK. Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients. World J Hepatol 2017; 9(9): 469-476
- URL: https://www.wjgnet.com/1948-5182/full/v9/i9/469.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i9.469